Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Asthma and Allergy Foundation of America Offers Free Online Course for Severe Asthma on February 19, 2019 at 7:33 am
Washington, DC, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Severe ASTHMA (Asthma Symptoms, Treatment, Health Management and Activities™) Care for Adults is a FREE self-paced course that helps adults ... […]
- Ask the Doctors: Runner's asthma triggered by noticeable exertion on February 19, 2019 at 3:01 am
Dear Doctor: I’ve noticed that after running, especially when I’ve really pushed myself, I’ll cough for a while. A friend says it’s something called exercise-induced asthma. Why is it happening? Dear ... […]
- Is it allergic asthma or something else? on February 18, 2019 at 4:11 pm
Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current lis... […]
- Breast pumps may put babies at asthma risk: Study on February 18, 2019 at 1:12 pm
Toronto, Feb 18 (PTI) Indirect breastfeeding — using pumps to extract milk from the breasts — can expose babies to potential pathogens that increase the risk of asthma and other respiratory infections ... […]
- Explore Asthma Monitoring Devices market trends and forecast from 2018 to 2025 on February 17, 2019 at 11:01 pm
News from QY Research, Inc. The market research report is a perfect tool for digging deep into critical aspects of the global Asthma Monitoring Devices market and closely understanding factors that in... […]
- Asthma classes in school may help reduce attacks on February 15, 2019 at 10:47 am
(Reuters Health) - School-age children with asthma who receive education on managing the condition may have fewer attacks, emergency room visits and hospitalizations than those who don’t get such clas... […]
- Shrinky Dinks Inspire Wearable That Predicts Oncoming Asthma Attacks on February 15, 2019 at 8:40 am
If you never created and played with Shrinky Dinks as a kid, they’re basically thin sheets of malleable plastic that are drawn on and then shrunk when put in the oven. The result is a very tiny and ha... […]
- Medical News Today: Does asthma run in the family? on February 14, 2019 at 4:51 pm
Asthma has a strong genetic component. This means that people with a family history of asthma are more likely to have it. However, genetics are not the only cause. Learn more about what might lead ... […]
- Smoothing out muscle in asthma on February 14, 2019 at 4:11 pm
Asthma is often treated with drugs that reduce airway inflammation. Saunders et al. now show that fevipiprant, a prostaglandin D 2 type 2 receptor antagonist, reduces smooth muscle mass in bronchial b... […]
via Bing News